Newstim, Inc.

10 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Oct 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 2, 2027
The maintenance fee for Cardiac device for treating Brugada syndrome (US 10,335,600) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
1 fee due Feb 8, 2027
The maintenance fee for System for Brugada syndrome presence-based electrical therapeutic stimulation delivery (US 11,717,690) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
1 fee due Jun 3, 2027
The maintenance fee for System for treating Brugada syndrome (US 10,493,284) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
1 fee due Nov 14, 2027
The maintenance fee for System for Brugada syndrome detection and treatment via electrical stimulation (US 11,980,762) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 9,392,949	Ventricular pacing in cardiac-related applications In force Term ends Oct 2, 2033 · From the USPTO record	In force	Term ends Oct 2, 2033	From the USPTO record
US 9,717,916	System for determination and utilization of cardiac electrical asynchrony data In force Ends no later than Oct 2, 2033 · From the USPTO record	In force	Ends no later than Oct 2, 2033	From the USPTO record
US 10,065,042	System For Cardiac Stimulation Optimization Utilizing Cardiac Asynchrony And Pulse Pressure Data In force Ends no later than Oct 2, 2033 · Low confidence	In force	Ends no later than Oct 2, 2033	Low confidence
US 10,493,284	System for treating Brugada syndrome In force Ends no later than Mar 30, 2037 · From the USPTO record	In force	Ends no later than Mar 30, 2037	From the USPTO record
US 11,980,762	System for Brugada syndrome detection and treatment via electrical stimulation In force Term ends Mar 30, 2037 · From the USPTO record	In force	Term ends Mar 30, 2037	From the USPTO record
US 12,397,164	System for multimodal brugada syndrome treatment via electrical stimulation In force Term ends Mar 30, 2037 · From the USPTO record	In force	Term ends Mar 30, 2037	From the USPTO record
US 11,033,744	System for electrical therapeutic stimulation-based treatment of Brugada syndrome In force Term ends Apr 23, 2037 · From the USPTO record	In force	Term ends Apr 23, 2037	From the USPTO record
US 10,335,600	Cardiac device for treating Brugada syndrome In force Term ends Jul 19, 2037 · From the USPTO record	In force	Term ends Jul 19, 2037	From the USPTO record
US 11,717,690	System for Brugada syndrome presence-based electrical therapeutic stimulation delivery In force Term ends Jul 24, 2037 · From the USPTO record	In force	Term ends Jul 24, 2037	From the USPTO record
US 11,395,922	System for Brugada syndrome detection and treatment In force Term ends Oct 13, 2037 · From the USPTO record	In force	Term ends Oct 13, 2037	From the USPTO record

Also on record, not counted in the 10: 26 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

Every application published under this name has become a patent.